Product Images Oxcarbazepine

This text provides information about Oxcarbazepine oral suspension in a strength of 300mg/5mL. It includes instructions for dispensing and usage, as well as storage guidelines. The text also mentions a Medication Guide for patients and the manufacturer details.*

This data provides information on the doses of Oxcarbazepine administered, along with a list of adverse reactions experienced by 86 individuals. The adverse reactions are categorized by body system, such as Body as a Whole, Digestive System, Nervous System, Respiratory System, Skin and Appendages, Special Senses, and Urogenital and Reproductive System. Common reactions include fatigue, nausea, headache, dizziness, anxiety, insomnia, coughing, and urinary tract infections. This information can be valuable for healthcare professionals to understand the potential side effects associated with the medication.*

This is a clinical trial data table showing the effects of different treatments on reducing the median baseline. The first trial is on pediatrics with two groups receiving either Oxcarbazepine or Placebo. The second trial is on adults with different dosages of Oxcarbazepine and a Placebo group. The percentage reduction in baseline median is shown for each treatment group.*

This seems to be a table showing the influence of different anti-epileptic drugs (AEDs) on the concentration levels of another drug called Oxcarbazepine. The table lists the AED, the dose range administered, and the mean change in concentration levels observed. The text mentions various percentage changes in concentration levels for different AEDs such as Carbamazepine, Phenobarbital, Phenytoin, Valproic acid, and Lamotrigine. The percentages indicate increases or decreases in drug concentration levels when co-administered with Oxcarbazepine.*

This is a table showing weight, dose in milligrams per day, and corresponding percentage values. The weight is listed in kilograms, and the dose ranges from 500 to 2100 mg/day. The percentage values vary for different weight ranges. This data seems to be related to a dosage recommendation or guideline based on weight for a certain substance or medication.*

This table provides a comparison of the incidence of events between placebo patients and those taking a specific drug for different indications. The data includes the number of patients, the relative risk, risk difference, and events per 1,000 patients for each of the indications, namely Epilepsy, Psychatric (Psychiatric), and Other. For example, in the case of Psychiatric patients, there were 85 events per 1,000 drug patients compared to 57 events per 1,000 placebo patients. The information can be used to evaluate the effectiveness and risks associated with the drug treatment for each indication.*

This document provides information on Oxcarbazepine dosage in mg/day and outlines the associated adverse reactions on various body systems. The adverse reactions include symptoms such as fatigue, nausea, headache, dizziness, somnolence, and more. Each reaction is categorized under the corresponding body system affected, with detailed percentages and dosages specified for each symptom.*

This text contains a list of adverse reactions associated with Oxcarbazepine. Some of the reactions mentioned are falling, nausea, diarrhea, vomiting, constipation, dyspepsia, back pain, dizziness, headache, ataxia, nervousness, amnesia, tremor, upper respiratory tract infection, epistaxis, chest infection, sinusitis, rash, abnormal vision, and more.*

This text seems to be a list of adverse reactions associated with the drug Oxc*hazepine. Adverse reactions are categorized by body system such as Whole Body, Digestive System, Nervous System, Respiratory System, Skin and Appendages, and Special Senses. Some of the reported adverse reactions include fatigue, allergy, asthenia, vomiting, nausea, constipation, headache, somnolence, dizziness, rhinitis, pneumonia, bruising, increased sweating, double vision, abnormal vision, and vertigo. This list provides useful information on potential side effects of the drug.*